Patents Assigned to Fovea Pharmaceuticals
  • Patent number: 9308125
    Abstract: The present technology relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and a guide operable to guide a needle into the interior of an eye, characterized in that it comprises means for displacing a superficial layer (1) of the eye over an underlying layer (2) of the eye as the plate is brought into contact with the eye before the needle is guided into the interior of the eye.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: April 12, 2016
    Assignees: FOVEA PHARMACEUTICALS, FONDATION OPHTALMOLOGIQUEADOLPHE DE ROTHSCHILD
    Inventors: Michel Paques, Pierre Roy
  • Patent number: 9249085
    Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: February 2, 2016
    Assignee: FOVEA PHARMACEUTICALS
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • Publication number: 20140350019
    Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 27, 2014
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • Patent number: 8808242
    Abstract: The invention relates to an apparatus for injection into an eye comprising of a means for displacing a conjunctival layer of the eye over an underlying scleral layer of the eye so as to form a fold in the conjunctival layer, and means for guiding a needle through the conjunctival layer once the fold has been formed.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: August 19, 2014
    Assignee: Fovea Pharmaceuticals
    Inventors: Michel Paques, Pierre Roy
  • Publication number: 20130315903
    Abstract: The invention is directed to the therapeutic use of arylsulfonamide derivatives.
    Type: Application
    Filed: December 9, 2011
    Publication date: November 28, 2013
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: Pierre Belichard, Didier Pruneau
  • Publication number: 20130253027
    Abstract: The invention is directed to the therapeutic use of arylsulfonamide derivatives.
    Type: Application
    Filed: December 9, 2011
    Publication date: September 26, 2013
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: Jean-Philippe Combal, Elisabeth Latour
  • Publication number: 20130211335
    Abstract: The invention relates to an apparatus for injection into an eye comprising of a means for displacing a conjunctival layer of the eye over an underlying scleral layer of the eye so as to form a fold in the conjunctival layer, and means for guiding a needle through the conjunctival layer once the fold has been formed.
    Type: Application
    Filed: November 2, 2011
    Publication date: August 15, 2013
    Applicant: FOVEA Pharmaceuticals
    Inventors: Michel Paques, Pierre Roy
  • Patent number: 8460242
    Abstract: The application relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and guiding means for guiding a needle into the interior of an eye, characterized in that the plate comprises a cut-out having an edge adapted to be positioned along the limbus delimiting the cornea and the sclera of the eye, so as to adjust the position of the guiding means with respect to the limbus.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: June 11, 2013
    Assignees: Fovea Pharmaceuticals, Foundation Ophtalmologiqueadolphe de Rothschild
    Inventors: Michel Paques, Pierre Roy
  • Publication number: 20130123271
    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 16, 2013
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: David Middlemiss, Caroline Leriche
  • Patent number: 8389530
    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 5, 2013
    Assignee: Fovea Pharmaceuticals
    Inventors: Caroline Leriche, Eric Auclair, Jacques Le Roux, David N. Middlemiss
  • Publication number: 20100030150
    Abstract: The application relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and guiding means for guiding a needle into the interior of an eye, characterized in that the plate comprises a cut-out having an edge adapted to be positioned along the limbus delimiting the cornea and the sclera of the eye, so as to adjust the position of the guiding means with respect to the limbus.
    Type: Application
    Filed: January 9, 2008
    Publication date: February 4, 2010
    Applicants: FOVEA PHARMACEUTICALS, FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD
    Inventors: Michel Paques, Pierre Roy
  • Publication number: 20100010452
    Abstract: The present technology relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and a guide operable to guide a needle into the interior of an eye, characterized in that it comprises means for displacing a superficial layer (1) of the eye over an underlying layer (2) of the eye as the plate is brought into contact with the eye before the needle is guided into the interior of the eye.
    Type: Application
    Filed: January 9, 2008
    Publication date: January 14, 2010
    Applicants: FOVEA PHARMACEUTICALS, FOUDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD
    Inventors: Michel Paques, Pierre Roy
  • Publication number: 20090285826
    Abstract: Pharmaceutical compositions for inhibiting, preventing or treating unwanted angiogenesis/neovascularization, including that of ocular tissues, contain agents that inhibit VEGF in combination with a second therapy, e.g., that elicited by serine proteases/thrombolytic compounds.
    Type: Application
    Filed: May 4, 2007
    Publication date: November 19, 2009
    Applicants: FOVEA PHARMACEUTICALS SA, FONDATION OPHTHALMOLOGIQUE ADOLPHE DE ROTHSCHILD
    Inventors: Sebastien Bonnel, José Sahel
  • Publication number: 20070270344
    Abstract: The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity.
    Type: Application
    Filed: March 15, 2007
    Publication date: November 22, 2007
    Applicant: Fovea Pharmaceuticals
    Inventor: Pierre Belichard